Aktiesnakken — August 2010
-
ok kunne heller ikke forstår det. Men interessant med et strategy update d. 14 september
-
ja de skal finde en partner til zalut. Cash is god
-
US: 70.000 cll patienter nye 15.000. Vel omkring 40% der kan blive refrac kunder
-
og så læg EU oveni
-
ved fuld penetration kan royalty blive 1,7 milliard!
-
men det er blue sky
-
ja det kan vi.
-
butter jeg har ikke noget på neuro, andet end at der skulle være data på vej
-
det er bendamustinen
-
ja rth, regnskabet bekræfter vores forudsætninger i gamechangeren at aftalen udover de 815 mill også giver en besparelse på 350 mill
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind